尼妥珠单抗联合调强适形放疗治疗鼻咽癌的近期临床疗效及远期预后分析  

Short-term clinical efficacy and long-term prognosis of nimotuzumab combined intensity modulated radiation therapy in nasopharyngeal carcinoma

作　　者：李文杰[1] 马庆林[1] 王亮[2] LI Wenjie;MAQinglin;WANG Liang(Department of Otolaryngology,the People’s Hospital of Anyang City,Anyang 455000,He’nan,China;Department of Otolaryngology,the First Affiliated Hospital of Zhengzhou University,Zhengzhou 450006,He’nan,China)

机构地区：[1]安阳市人民医院耳鼻咽喉科,河南安阳455000 [2]郑州大学第一附属医院耳鼻咽喉科,郑州450006

出　　处：《癌症进展》2023年第18期2062-2065,共4页Oncology Progress

摘　　要：目的分析尼妥珠单抗联合调强适形放疗(IMRT)治疗鼻咽癌的近期临床疗效及对远期预后的影响。方法将102例鼻咽癌患者按治疗方式的不同分为A组(n=52,尼妥珠单抗联合IMRT)和B组(n=50,尼妥珠单抗联合常规放疗)。比较两组患者近期疗效、相关实验室指标、生存率、复发率及治疗期间并发症发生情况。结果A组患者总有效率高于B组,差异有统计学意义(P﹤0.05)。治疗后6周,两组患者鳞状上皮细胞癌抗原(SCC-Ag)、高迁移率族蛋白B1(HMGB1)水平均较治疗前降低,且A组患者SCC-Ag、HMGB1水平均低于B组,差异均有统计学意义(P﹤0.05)。A组患者3年生存率高于B组,3年复发率低于B组,差异均有统计学意义(P﹤0.05)。A组患者并发症总发生率低于B组,差异有统计学意义(P﹤0.05)。结论尼妥珠单抗联合IMRT治疗鼻咽癌患者的近期治疗效果显著,能有效降低血清肿瘤标志物水平,提高患者生存率。Objective To analyze the short-term clinical efficacy and long-term prognosis of nimotuzumab combined with intensity modulated radiation therapy(IMRT)in the treatment of nasopharyngeal carcinoma.Method A total of 102 patients with nasopharyngeal carcinoma were divided into group A(n=52,treated with nimotuzumab+IMRT)and group B(n=50,treated with nimotuzumab+conventional radiotherapy)according to different treatment methods.The short-term efficacy,relevant laboratory indicators,survival rate,recurrence rate and incidence of complications during treatment were compared between the two groups.Result The total effective rate of group A was significantly higher than that of group B(P<0.05).The levels of squamous cell carcinoma antigen(SCC-Ag)and high mobility group protein B1(HMGB1)at 6 months after treatment in both groups were lower than those before treatment,with lower levels in group A than those in group B(P<0.05).The 3-year survival rate of group A was significantly higher than that of group B,and the 3-year recurrence rate was lower than that of group B(P<0.05).The total incidence of complications in group A was significantly lower than that in group B(P<0.05).Conclusion Nimotuzumab+IMRT has significant short-term efficacy in patients with nasopharyngeal carcinoma,which can effectively decrease levels of serum tumor marker,and improve survival rate.

关 键 词：尼妥珠单抗 调强适形放疗 鼻咽癌 远期预后 

分 类 号：R739.6[医药卫生—肿瘤]